Julie J Ruterbusch1, Rouba Ali-Fehmi2, Sara H Olson3, Shawnita Sealy-Jefferson4, Benjamin A Rybicki5, Sharon Hensley-Alford6, Mohamed A Elshaikh7, Arthur R Gaba8, Daniel Schultz8, Adnan R Munkarah9, Michele L Cote10. 1. Barbara Ann Karmanos Cancer Institute, Detroit, MI; Department of Oncology, Wayne State University, Detroit, MI. Electronic address: ruterbus@med.wayne.edu. 2. Barbara Ann Karmanos Cancer Institute, Detroit, MI; Department of Pathology, Wayne State University, Detroit, MI. 3. Memorial Sloan-Kettering Cancer Center, New York, NY. 4. Barbara Ann Karmanos Cancer Institute, Detroit, MI; Department of Family Medicine and Public Health Sciences, Wayne State University, Detroit, MI. 5. Department of Public Health, Henry Ford Health System, Detroit, MI. 6. Department of Public Health, Henry Ford Health System, Detroit, MI; Department of Women's Health, Henry Ford Health System, Detroit, MI. 7. Department of Radiation Oncology, Henry Ford Health System, Detroit, MI. 8. Department of Pathology, Henry Ford Health System, Detroit, MI. 9. Department of Women's Health, Henry Ford Health System, Detroit, MI. 10. Barbara Ann Karmanos Cancer Institute, Detroit, MI; Department of Oncology, Wayne State University, Detroit, MI.
Abstract
OBJECTIVE: There are known disparities in endometrial cancer survival with black women who experience a greater risk of death compared with white women. The purpose of this investigation was to evaluate the role of comorbid conditions as modifiers of endometrial cancer survival by race. STUDY DESIGN: Two hundred seventy-one black women and 356 white women who had been diagnosed with endometrial cancer from 1990-2005 were identified from a large urban integrated health center. A retrospective chart review was conducted to gather information on comorbid conditions and other known demographic and clinical predictors of survival. RESULTS: Black women experienced a higher hazard of death from any cause (hazard ratio [HR] 1.51; 95% confidence interval [CI], 1.22-1.87) and from endometrial cancer (HR, 2.42; 95% CI, 1.63-3.60). After adjustment for known clinical prognostic factors and comorbid conditions, the hazard of death for black women was elevated but no longer statistically significant for overall survival (HR, 1.22; 95% CI, 0.94-1.57), and the hazard of death from endometrial cancer remained significantly increased (HR, 2.27; 95% CI, 1.39-3.68). Both black and white women with a history of hypertension experienced a lower hazard of death from endometrial cancer (HR, 0.47; 95% CI, 0.23-0.98; and HR, 0.35; 95% CI, 0.19-0.67, respectively). CONCLUSION: The higher prevalence of comorbid conditions among black women does not explain fully the racial disparities that are seen in endometrial cancer survival. The association between hypertension and a lower hazard of death from endometrial cancer is intriguing, and further investigation into the underlying mechanism is needed.
OBJECTIVE: There are known disparities in endometrial cancer survival with black women who experience a greater risk of death compared with white women. The purpose of this investigation was to evaluate the role of comorbid conditions as modifiers of endometrial cancer survival by race. STUDY DESIGN: Two hundred seventy-one black women and 356 white women who had been diagnosed with endometrial cancer from 1990-2005 were identified from a large urban integrated health center. A retrospective chart review was conducted to gather information on comorbid conditions and other known demographic and clinical predictors of survival. RESULTS: Black women experienced a higher hazard of death from any cause (hazard ratio [HR] 1.51; 95% confidence interval [CI], 1.22-1.87) and from endometrial cancer (HR, 2.42; 95% CI, 1.63-3.60). After adjustment for known clinical prognostic factors and comorbid conditions, the hazard of death for black women was elevated but no longer statistically significant for overall survival (HR, 1.22; 95% CI, 0.94-1.57), and the hazard of death from endometrial cancer remained significantly increased (HR, 2.27; 95% CI, 1.39-3.68). Both black and white women with a history of hypertension experienced a lower hazard of death from endometrial cancer (HR, 0.47; 95% CI, 0.23-0.98; and HR, 0.35; 95% CI, 0.19-0.67, respectively). CONCLUSION: The higher prevalence of comorbid conditions among black women does not explain fully the racial disparities that are seen in endometrial cancer survival. The association between hypertension and a lower hazard of death from endometrial cancer is intriguing, and further investigation into the underlying mechanism is needed.
Authors: Veronica Wendy Setiawan; Malcolm C Pike; Laurence N Kolonel; Abraham M Nomura; Marc T Goodman; Brian E Henderson Journal: Am J Epidemiol Date: 2006-11-07 Impact factor: 4.897
Authors: Zachary Nicholas; Nan Hu; Jian Ying; Patrick Soisson; Mark Dodson; David K Gaffney Journal: Am J Clin Oncol Date: 2014-04 Impact factor: 2.339
Authors: Terri Madison; David Schottenfeld; Sherman A James; Ann G Schwartz; Stephen B Gruber Journal: Am J Public Health Date: 2004-12 Impact factor: 9.308
Authors: Ashley S Felix; Eric M McLaughlin; Bette J Caan; David E Cohn; Garnet L Anderson; Electra D Paskett Journal: Int J Cancer Date: 2019-10-31 Impact factor: 7.396
Authors: Ashley S Felix; David E Cohn; Theodore M Brasky; Richard Zaino; Kay Park; David G Mutch; William T Creasman; Premal H Thaker; Joan L Walker; Richard G Moore; Shashikant B Lele; Saketh R Guntupalli; Levi S Downs; Christa I Nagel; John F Boggess; Michael L Pearl; Olga B Ioffe; Marcus E Randall; Louise A Brinton Journal: Am J Obstet Gynecol Date: 2018-08-07 Impact factor: 8.661
Authors: Albina N Minlikeeva; Jo L Freudenheim; Rikki A Cannioto; J Brian Szender; Kevin H Eng; Francesmary Modugno; Roberta B Ness; Michael J LaMonte; Grace Friel; Brahm H Segal; Kunle Odunsi; Paul Mayor; Emese Zsiros; Barbara Schmalfeldt; Rüdiger Klapdor; Thilo Dӧrk; Peter Hillemanns; Linda E Kelemen; Martin Kӧbel; Helen Steed; Anna de Fazio; Susan J Jordan; Christina M Nagle; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Robert Edwards; Keitaro Matsuo; Mika Mizuno; Beth Y Karlan; Susanne K Kjær; Estrid Høgdall; Allan Jensen; Joellen M Schildkraut; Kathryn L Terry; Daniel W Cramer; Elisa V Bandera; Lisa E Paddock; Lambertus A Kiemeney; Leon F Massuger; Jolanta Kupryjanczyk; Andrew Berchuck; Jenny Chang-Claude; Brenda Diergaarde; Penelope M Webb; Kirsten B Moysich Journal: Cancer Causes Control Date: 2017-03-14 Impact factor: 2.506
Authors: David A Barrington; Jennifer A Sinnott; Danaye Nixon; Tasleem J Padamsee; David E Cohn; Kemi M Doll; Macarius M Donneyong; Ashley S Felix Journal: Am J Obstet Gynecol Date: 2022-03-10 Impact factor: 10.693
Authors: Ashley S Felix; D Scott McMeekin; David Mutch; Joan L Walker; William T Creasman; David E Cohn; Shamshad Ali; Richard G Moore; Levi S Downs; Olga B Ioffe; Kay J Park; Mark E Sherman; Louise A Brinton Journal: Gynecol Oncol Date: 2015-09-01 Impact factor: 5.482